

## Accepted Manuscript

C3-mediated extravascular hemolysis in PNH on eculizumab:  
mechanism and clinical implications


Rosario Notaro , Michela Sica

PII: S0037-1963(18)30062-3  
DOI: [10.1053/j.seminhematol.2018.05.014](https://doi.org/10.1053/j.seminhematol.2018.05.014)  
Reference: YSTEM 50977

To appear in: *Seminars in Hematology*

Received date: 7 May 2018  
Accepted date: 29 May 2018

Please cite this article as: Rosario Notaro , Michela Sica , C3-mediated extravascular hemolysis in PNH on eculizumab: mechanism and clinical implications, *Seminars in Hematology* (2018), doi: [10.1053/j.seminhematol.2018.05.014](https://doi.org/10.1053/j.seminhematol.2018.05.014)



This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

***C3-mediated extravascular hemolysis in PNH on eculizumab: mechanism and clinical implications.***

**Rosario Notaro & Michela Sica**

Laboratory of Cancer Genetics and Gene Transfer, Core Research Laboratory –

Istituto per lo Studio, la Prevenzione e la Rete Oncologica (ISPRO)

viale Pieraccini 6, 50139 Florence (Italy).

Phone: +39 055 794 4557.

e-mail: r.notaro@ispro.toscana.it

**Abstract**

The introduction of eculizumab, a human monoclonal antibody against the C5 component of complement, has changed radically the management of paroxysmal nocturnal hemoglobinuria (PNH). The blockade of the terminal complement pathway by eculizumab abrogates intravascular hemolysis, reduces the transfusion requirement and the risk of thrombosis in most of hemolytic PNH patients. However, in almost all PNH patients on eculizumab arises a fraction of PNH red cells that bind fragments of C3 and become a potential target of phagocytosis by macrophages. Eventually, this phagocytosis results in a variable degree of extravascular hemolysis that may reduce clinical benefits of eculizumab and, in fact, about one fourth of patients remain transfusion-dependent.

The treatment of the few PNH patients in which this *de novo* extravascular hemolysis become clinically relevant is still unsatisfactory. Nevertheless, the investigations of the mechanisms responsible of the extravascular hemolysis on eculizumab have resulted in the development of novel strategies for complement blockade that could overcome this condition.

Download English Version:

<https://daneshyari.com/en/article/8734779>

Download Persian Version:

<https://daneshyari.com/article/8734779>

[Daneshyari.com](https://daneshyari.com)